2022 American Transplant Congress
The Impact of Donor’s Metabolic Syndrome Factor on Living Kidney Transplantation
*Purpose: Because donors for kidney transplantation are also aging in Japan, it is not uncommon that donors have metabolic syndrome (Met-S). It is necessary to…2022 American Transplant Congress
Defining the Characteristics and Graft Outcomes of Kidney Transplant Recipients with Pre-Transplant Elevated Plasma Oxalate Levels
*Purpose: The objective of this study is to compare graft outcomes for patients with pre-transplant elevated plasma oxalate (Pox) compared to a matched cohort.*Methods: Kidney…2022 American Transplant Congress
A Large-Scale National Cohort Study Assessing the Impact of Diabetes and Obesity on Kidney Transplant Outcomes
*Purpose: Type 2 Diabetes Mellitus (T2DM) is the most common cause of renal failure in patients undergoing kidney transplantation (KT) and highly correlated with obesity.…2022 American Transplant Congress
Glucose Variability in Kidney Transplantation: Pre-Transplant and Post-Transplant Continuous Glucose Monitoring
*Purpose: Continuous glucose monitoring (CGM) provides a 24-hour view of glucose values and information on glycemic variability and additional indices such as the glucose management…2022 American Transplant Congress
Epidemiology of Post Transplant Diabetes Mellitus
Renal Medicine Department, The Royal Hospital, Bausher, Oman
*Purpose: Diabetes mellitus (DM) is a common non-communicable disease and have serious metabolic complications that contribute to death, major cardiovascular events, organs failure, and increased…2022 American Transplant Congress
Sodium-Glucose Co-Transporter 2 Inhibitors; Short-Term Outcome in Diabetic Kidney Transplant Recipients
*Purpose: The idea of using SGLT2i in kidney transplant recipients (KTR) is a legitimate one after the recent encouraging data for their use in other…2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…2022 American Transplant Congress
Intermediate Term Outcomes of SGLT2 Inhibitors Amongst Diabetic Kidney Transplant Recipients
1Pharmacy, VCUHS, Richmond, VA, 2VCUHS, Richmond, VA
*Purpose: The use of Sodium Glucose Linked Transporter Inhibitors (SGLT-2i) among non-transplant diabetic patients with chronic kidney disease (CKD) has demonstrated reduced cardiovascular mortality, delayed…2022 American Transplant Congress
Cryptococcal Meningitis Presenting as SIADH in a Heart Transplant Recipient
Temple University Hospital, Philadelphia, PA
*Purpose: Cryptococcal meningitis is a potentially fatal invasive fungal infection in solid organ transplant recipients. Meningoencephalitis is the most common clinical manifestation of cryptococcal infection.…2021 American Transplant Congress
Evaluation of Safety and Efficacy of PCSK9 Inhibitors in Solid Organ Transplant Recipients: Experience at a Large Multi-organ Transplant Center
*Purpose: The aim of the study was to characterize the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in solid organ transplant…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »